Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q4 2018 · 10-K
Revenue$616.83M$616.83Mderived−0.7% vs Q4 2017 Net Income-$828.50M-$828.50MN/M vs Q4 2017 EPS Diluted-$27.73-$27.73N/M vs Q4 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
−3.7%
Operating Incomederived-$227,054,000N/M Operating Cash Flowderived$105,009,000+51.4% Free Cash Flowderived$51,135,000+18.1% Margins · derivedGross margin53.9%−1.6 pt vs Q4 2017
Operating margin-36.8%−44.2 pt vs Q4 2017
Net margin-134.3%−147.6 pt vs Q4 2017
ended Dec 31, 2018 · filed Apr 1, 2019 · 91 d after period end